Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Novo Nordisk’s weekly GLP-1 diabetes injection semaglutide ... year. Ozempic is approved for use in two therapeutic dosages, 0.5 mg and 1 mg, and will be launched in a special pen.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Ozempic is a brand-name, injectable semaglutide medication ... price for Ozempic is $968.52 per pen without insurance. While this drug can be expensive, Novo Nordisk offers a savings card for ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes (T2D) and Wegovy injections for weight management. Any price reduction ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won ... in which the promise of Ozempic in CKD became clear. Novo stopped a phase 3b trial of semaglutide, the active ...

Novo Nordisk NVO is scheduled ... especially semaglutide. Notably, semaglutide, a GLP-1 agonist, is approved as an Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D ...